Arvinas (ARVN) Non-Current Assets (2017 - 2026)
Arvinas (ARVN) recorded quarterly Non-Current Assets of $16.8 million in Q1 2026, down 2.33% quarter-over-quarter from $17.2 million in Q4 2025, and down 21.5% on a YoY basis from $21.4 million in Q1 2025.
Arvinas (ARVN) Non-Current Assets (2017 - 2026) Analysis & Trends
Arvinas' Non-Current Assets history runs 10 years deep, the most recent figure standing at $16.8 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 21.5% year-over-year to $16.8 million; the TTM figure through Mar 2026 stood at $71.8 million (down 16.51% YoY), while the FY2025 annual figure was $17.2 million, down 28.63% from the prior year.
- Non-Current Assets was $16.8 million for Q1 2026 at Arvinas, down from $17.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $31.3 million in Q1 2022 to a low of $16.8 million in Q1 2026.
- Historically, Non-Current Assets has averaged $23.8 million across 5 years, with a median of $24.1 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets surged 87.81% in 2022, then slumped 30.43% in 2024.
- A 5-year view of Non-Current Assets shows it stood at $28.6 million in 2022, then fell by 14.69% to $24.4 million in 2023, then dropped by 1.23% to $24.1 million in 2024, then retreated by 28.63% to $17.2 million in 2025, then dropped by 2.33% to $16.8 million in 2026.
- The last three Non-Current Assets figures came in at $16.8 million (Q1 2026), $17.2 million (Q4 2025), and $18.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 16.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.80 Mn |
| Dec 31, 2025 | 17.20 Mn |
| Sep 30, 2025 | 18.00 Mn |
| Jun 30, 2025 | 19.80 Mn |
| Mar 31, 2025 | 21.40 Mn |
| Dec 31, 2024 | 24.10 Mn |
| Sep 30, 2024 | 17.60 Mn |
| Jun 30, 2024 | 22.90 Mn |
| Mar 31, 2024 | 22.30 Mn |
| Dec 31, 2023 | 24.40 Mn |
| Sep 30, 2023 | 25.30 Mn |
| Jun 30, 2023 | 26.80 Mn |
| Mar 31, 2023 | 27.60 Mn |
| Dec 31, 2022 | 28.60 Mn |
| Sep 30, 2022 | 30.10 Mn |
| Jun 30, 2022 | 30.60 Mn |
| Mar 31, 2022 | 31.30 Mn |
| Dec 31, 2021 | 29.10 Mn |
| Sep 30, 2021 | 28.71 Mn |
| Jun 30, 2021 | 16.29 Mn |